US politics live: Bombshell audio reveals Trump threat to ‘bomb the sh*t out of Moscow and Beijing'
A bombshell audio recording of US President Donald Trump threatening to 'bomb the sh-- out of Moscow and Beijing' has been released, along with Vladimir Putin's gobsmacked reaction.
A recording of a private meeting during a fundraiser appears to expose what Mr Trump actually told Russia and China in phone calls in his first term, The Sun reports.
The audio from 2024 captures Mr Trump revealing what he claimed to have said during his 2017-2021 presidency to his Russian counterpart.
He's heard saying: 'With Putin I said, 'If you go into Ukraine, I'm going to bomb the s*** out of Moscow. I'm telling you I have no choice.''
Later in the recording, the US President can also be heard claiming he gave a similar warning to China's President Xi Jinping if he invaded Taiwan.
The release of the recordings comes after Russia pummelled Ukraine overnight with its largest missile and drone attack in more than three years of war, claiming to have targeted an airfield in a region bordering Poland.
Earlier, Mr Trump said he would ramp up arms deliveries to Ukraine and accused Mr Putin of spouting 'bulls--t' on Ukraine.
The latest strike, which regional officials said had killed one civilian in the Khmelnytsky region, beat a previous Russian record of firing 550 drones and missiles at Ukraine set last week.
The air force announced that Russia attacked with 728 drones and 13 missiles, specifying that its air defence systems intercepted 711 drones and destroyed seven missiles.
'This is a telling attack — and it comes precisely at a time when so many efforts have been made to achieve peace, to establish a ceasefire, and yet only Russia continues to rebuff them all,' President Volodymyr Zelensky wrote on social media.
Mr Zelensky, who was visiting Rome and met with Pope Leo XIV, called for Ukraine's allies to step up sanctions on Russia, particularly on its energy sector — an important revenue stream for the Russian war chest.
'Our partners know how to apply pressure in a way that will force Russia to think about ending the war, not launching new strikes,' Mr Zelensky said.
Follow our live updates.
Originally published as US politics live: Bombshell audio reveals Trump threat to 'bomb the sh*t out of Moscow and Beijing'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
21 minutes ago
- Perth Now
Rubio makes first visit to Asia as Trump tariffs loom
US Secretary of State Marco Rubio will meet Southeast Asian counterparts in his first visit to Asia since taking office, and will try to reassure them the region is a priority for Washington, even as President Donald Trump targets it in his global tariff offensive. Washington's top diplomat will meet foreign ministers of the 10-member Association of Southeast Asian Nations gathered in Kuala Lumpur, and also hold talks with Russian Foreign Minister Sergei Lavrov who is in the Malaysian capital, according to the US State Department. Rubio's trip is part of an effort to renew US focus on the Indo-Pacific and look beyond the conflicts in the Middle East and Europe that have consumed much of the Trump administration's attention, with Rubio balancing dual responsibilities as secretary of state and national security adviser. However, Trump's global tariff strategy is likely to cast a shadow over the trip, after the president announced steep tariffs to take effect on August 1 on six ASEAN members, including Malaysia, as well as on close allies Japan and South Korea. Rubio will nevertheless seek to firm up US relationships with partners and allies, who have been unnerved by the tariffs, and is likely to press the case that the United States remains a better partner than China, Washington's main strategic rival, experts say. Rubio will also meet Lavrov later on Thursday, according to the US State Department schedule. It will be the second in-person meeting between Rubio and Lavrov, and comes at a time when Trump has grown increasingly frustrated with Russian President Vladimir Putin as the war in Ukraine drags on. China's Foreign Minister Wang Yi is also expected to join talks from Thursday, but it was unclear if Rubio would meet him. A senior US State Department official told reporters on Monday that among Rubio's priorities on the trip was reaffirming Washington's commitment to the region, not just for its sake but because it promoted American prosperity and security. Security co-operation is a top priority, including the strategic South China Sea, and combating transnational crime, narcotics, scam centres, and trafficking in persons, the State Department official said. As well as their unease about Trump's tariff policies, many in the Indo-Pacific have doubts about the willingness of his "America First" administration to fully engage diplomatically and economically with the region. Trump said this week he would impose a 25 per cent tariff on Japan and South Korea and also took aim at ASEAN nations, announcing a 25 per cent levy on Malaysia, 32 per cent on Indonesia, 36 per cent on Cambodia and Thailand, and 40 per cent on Laos and Myanmar. Trump has also upset another key Indo-Pacific ally, Australia, which said on Wednesday it was "urgently seeking more detail" on his threat to raise tariffs to 200 per cent on pharmaceutical imports. According to a draft joint communique seen by Reuters, ASEAN foreign ministers will express "concern over rising global trade tensions and growing uncertainties in the international economic landscape, particularly the unilateral actions relating to tariffs". The draft before the latest US tariff rates were announced, does not mention the United States and uses language similar to an ASEAN leaders' statement in May. Both say tariffs are "counterproductive and risk exacerbating global economic fragmentation". Only Vietnam has secured a deal with Trump, which lowers the levy to 20 per cent from 46 per cent initially.
Sydney Morning Herald
an hour ago
- Sydney Morning Herald
The Australian pharma giant on Trump's tariff hit list
Australian pharmaceutical giant CSL is on tariff watch after US President Donald Trump threatened to slug pharmaceutical imports into the US with a 200 per cent impost, two months after asking the US government to carefully consider the consequences of the measure. CSL is an $117 billion ASX giant and the nation's biggest player in pharmaceuticals, a sector responsible for about $2.2 billion in exports to the US. While CSL is exposed to the hefty tariffs proposed by the Trump administration, analysts said the company was insured by its large overseas operations, including its facilities in the US, and the critical nature of the medicines it makes. Founded in 1916 as a vaccine manufacturer for the Australian government, CSL makes vaccines (including COVID-19 vaccines), antivenom, and plasma-derived medicines. It still makes products in Australia and exports them, with Morningstar analyst Shane Ponraj saying on Thursday that while there are other healthcare stocks on the Australian sharemarket, the Trump tariffs 'will only directly affect CSL.' However despite the risk, Ponraj said that CSL's ability to adjust its supply chain, shifting its reliance onto its US facilities, should allow the company to weather the storm if the US government follows through on the tariff threat. 'CSL processes some US products in Australia but has many facilities in the US and some flexibility to adjust supply chains,' Ponraj said. 'While increasing uncertainty near-term, we don't expect CSL's earnings are materially affected because tariffs this high are unlikely to persist, and CSL can adopt by onshoring manufacturing.' In May, in response to the US government's request for public comments on its investigation into pharmaceutical imports, CSL submitted a seven-page letter opposing the introduction of tariffs. 'Broadly imposing tariffs on the pharmaceutical sector would disrupt and limit US patients' access to therapies, increase costs for patients and the healthcare system, raise manufacturing costs, and limit company resources that are available for biomedical innovation, capital investments, and jobs in the US,' it read.
The Age
an hour ago
- The Age
The Australian pharma giant on Trump's tariff hit list
Australian pharmaceutical giant CSL is on tariff watch after US President Donald Trump threatened to slug pharmaceutical imports into the US with a 200 per cent impost, two months after asking the US government to carefully consider the consequences of the measure. CSL is an $117 billion ASX giant and the nation's biggest player in pharmaceuticals, a sector responsible for about $2.2 billion in exports to the US. While CSL is exposed to the hefty tariffs proposed by the Trump administration, analysts said the company was insured by its large overseas operations, including its facilities in the US, and the critical nature of the medicines it makes. Founded in 1916 as a vaccine manufacturer for the Australian government, CSL makes vaccines (including COVID-19 vaccines), antivenom, and plasma-derived medicines. It still makes products in Australia and exports them, with Morningstar analyst Shane Ponraj saying on Thursday that while there are other healthcare stocks on the Australian sharemarket, the Trump tariffs 'will only directly affect CSL.' However despite the risk, Ponraj said that CSL's ability to adjust its supply chain, shifting its reliance onto its US facilities, should allow the company to weather the storm if the US government follows through on the tariff threat. 'CSL processes some US products in Australia but has many facilities in the US and some flexibility to adjust supply chains,' Ponraj said. 'While increasing uncertainty near-term, we don't expect CSL's earnings are materially affected because tariffs this high are unlikely to persist, and CSL can adopt by onshoring manufacturing.' In May, in response to the US government's request for public comments on its investigation into pharmaceutical imports, CSL submitted a seven-page letter opposing the introduction of tariffs. 'Broadly imposing tariffs on the pharmaceutical sector would disrupt and limit US patients' access to therapies, increase costs for patients and the healthcare system, raise manufacturing costs, and limit company resources that are available for biomedical innovation, capital investments, and jobs in the US,' it read.
